Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The FDA is tightening its regulatory policy around COVID vaccines with a new framework that raises the bar for certain ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots.